Publication Name	World Journal of Meta-Analysis
Manuscript ID	61346
Country	India

Received	2020-12-03 08:15
Peer-Review Started	2020-12-03 08:15
To Make the First Decision
Return for Revision	2021-05-06 06:00
Revised	2021-05-20 06:40
Second Decision	2021-06-17 12:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-06-17 12:43
Articles in Press	2021-06-17 12:43
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-06-21 01:00
Typeset the Manuscript	2021-06-27 14:46
Publish the Manuscript Online	2021-07-12 10:23

ISSN	2308-3840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Neurosciences
Manuscript Type	Minireviews
Article Title	Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview
Manuscript Source	Unsolicited Manuscript
All Author List	Bijaylaxmi Behera
ORCID	Author(s) ORCID Number Bijaylaxmi Behera http://orcid.org/0000-0001-9061-7677
Funding Agency and Grant Number
Corresponding Author	Bijaylaxmi Behera, MBBS, MD, Chief Physician, Department of Neonatology, Chaitanya Hospital, Sector 44, Chandigarh 160044, India. jollybubu2008@gmail.com
Key Words	CHERISH; Nusinersen; Spinal muscular atrophy; Survival motor neuron; NURTURE
Core Tip	Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease, with incidence of 1 in 5000 to 1 in 10000 live births. This review provides an elaborative knowledge regarding the current most effective drug for SMA, Nusinersen. A brief discussion on other treatment modalities that are under trials is also provided.
Publish Date	2021-07-12 10:23
Citation	Behera B. Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview. World J Meta-Anal 2021; 9(3): 277-285
URL	https://www.wjgnet.com/2308-3840/full/v9/i3/277.htm
DOI	https://dx.doi.org/10.13105/wjma.v9.i3.277

Full Article (PDF)	WJMA-9-277.pdf
Full Article (Word)	WJMA-9-277.docx
Manuscript File	61346-Review-FilipodiaCL.docx
Answering Reviewers	61346-Answering reviewers.pdf
Audio Core Tip	61346-Audio core tip.aac
Conflict-of-Interest Disclosure Form	61346-Conflict-of-interest statement.pdf
Copyright License Agreement	61346-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	61346-Language certificate.pdf
Peer-review Report	61346-Peer-review(s).pdf
Scientific Misconduct Check	61346-Scientific misconduct check.pdf
Scientific Editor Work List	61346-Scientific editor work list.pdf